TY - JOUR
T1 - The blood proteome of imminent lung cancer diagnosis
AU - Albanes, Demetrius
AU - Alcala, Karine
AU - Alcala, Nicolas
AU - Amos, Christopher I.
AU - Arslan, Alan A.
AU - Bassett, Julie K.
AU - Brennan, Paul
AU - Cai, Qiuyin
AU - Chen, Chu
AU - Feng, Xiaoshuang
AU - Freedman, Neal D.
AU - Guida, Florence
AU - Hung, Rayjean J.
AU - Hveem, Kristian
AU - Johansson, Mikael
AU - Johansson, Mattias
AU - Koh, Woon Puay
AU - Langhammer, Arnulf
AU - Milne, Roger L.
AU - Muller, David
AU - Onwuka, Justina
AU - Sørgjerd, Elin Pettersen
AU - Robbins, Hilary A.
AU - Sesso, Howard D.
AU - Severi, Gianluca
AU - Shu, Xiao Ou
AU - Sieri, Sabina
AU - Smith-Byrne, Karl
AU - Stevens, Victoria
AU - Tinker, Lesley
AU - Tjønneland, Anne
AU - Visvanathan, Kala
AU - Wang, Ying
AU - Wang, Renwei
AU - Weinstein, Stephanie
AU - Yuan, Jian Min
AU - Zahed, Hana
AU - Zhang, Xuehong
AU - Zheng, Wei
N1 - Generated from Scopus record by KAUST IRTS on 2023-09-21
PY - 2023/12/1
Y1 - 2023/12/1
N2 - Identification of risk biomarkers may enhance early detection of smoking-related lung cancer. We measured between 392 and 1,162 proteins in blood samples drawn at most three years before diagnosis in 731 smoking-matched case-control sets nested within six prospective cohorts from the US, Europe, Singapore, and Australia. We identify 36 proteins with independently reproducible associations with risk of imminent lung cancer diagnosis (all p < 4 × 10−5). These include a few markers (e.g. CA-125/MUC-16 and CEACAM5/CEA) that have previously been reported in studies using pre-diagnostic blood samples for lung cancer. The 36 proteins include several growth factors (e.g. HGF, IGFBP-1, IGFP-2), tumor necrosis factor-receptors (e.g. TNFRSF6B, TNFRSF13B), and chemokines and cytokines (e.g. CXL17, GDF-15, SCF). The odds ratio per standard deviation range from 1.31 for IGFBP-1 (95% CI: 1.17–1.47) to 2.43 for CEACAM5 (95% CI: 2.04–2.89). We map the 36 proteins to the hallmarks of cancer and find that activation of invasion and metastasis, proliferative signaling, tumor-promoting inflammation, and angiogenesis are most frequently implicated.
AB - Identification of risk biomarkers may enhance early detection of smoking-related lung cancer. We measured between 392 and 1,162 proteins in blood samples drawn at most three years before diagnosis in 731 smoking-matched case-control sets nested within six prospective cohorts from the US, Europe, Singapore, and Australia. We identify 36 proteins with independently reproducible associations with risk of imminent lung cancer diagnosis (all p < 4 × 10−5). These include a few markers (e.g. CA-125/MUC-16 and CEACAM5/CEA) that have previously been reported in studies using pre-diagnostic blood samples for lung cancer. The 36 proteins include several growth factors (e.g. HGF, IGFBP-1, IGFP-2), tumor necrosis factor-receptors (e.g. TNFRSF6B, TNFRSF13B), and chemokines and cytokines (e.g. CXL17, GDF-15, SCF). The odds ratio per standard deviation range from 1.31 for IGFBP-1 (95% CI: 1.17–1.47) to 2.43 for CEACAM5 (95% CI: 2.04–2.89). We map the 36 proteins to the hallmarks of cancer and find that activation of invasion and metastasis, proliferative signaling, tumor-promoting inflammation, and angiogenesis are most frequently implicated.
UR - https://www.nature.com/articles/s41467-023-37979-8
UR - http://www.scopus.com/inward/record.url?scp=85160945555&partnerID=8YFLogxK
U2 - 10.1038/s41467-023-37979-8
DO - 10.1038/s41467-023-37979-8
M3 - Article
C2 - 37264016
SN - 2041-1723
VL - 14
JO - Nature Communications
JF - Nature Communications
IS - 1
ER -
